Coronavirus Update: Sanofi And GSK’s Vaccine Suffers Setback
Plus: Pfizer On Track In US, But Needs More Time In India
Executive Summary
While the new mRNA-based vaccines grow closer to market, Sanofi and GSK's more established approach experiences a serious setback.US authorization in sight for Pfizer/BioNTech after positive advisory committee vote. Pfizer Seeks More Time For EUA Presentation In India.
You may also be interested in...
Sanofi/GSK Next-Generation COVID-19 Vaccine Shows Promise As Booster
Phase III data from two studies of the adjuvanted recombinant vaccine candidate showed increases in neutralizing antibody titers against the original SARS-CoV-2 strain and variants of concern.
Sanofi And GSK’s Much-Delayed COVID-19 Vaccine Ready To File, But Role Looks Limited
Tipped as one of the most likely to succeed back in early 2020, the delayed development of the adjuvanted protein-based COVID-19 vaccine been humbling for both companies.
Sanofi And GSK’s Much-Delayed COVID-19 Vaccine Ready To File, But Role Looks Limited
Tipped as one of the most likely to succeed back in early 2020, the delayed development of the adjuvanted protein-based COVID-19 vaccine been humbling for both companies.